State of Wisconsin Investment Board grew its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 11.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,159 shares of the biotechnology company’s stock after buying an additional 4,644 shares during the quarter. State of Wisconsin Investment Board owned 0.10% of United Therapeutics Corporation worth $5,292,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the company. Old Mutual Global Investors UK Ltd. boosted its holdings in shares of United Therapeutics Corporation by 30.3% in the third quarter. Old Mutual Global Investors UK Ltd. now owns 970,846 shares of the biotechnology company’s stock valued at $113,773,000 after buying an additional 225,953 shares during the period. Empirical Finance LLC boosted its holdings in United Therapeutics Corporation by 8.3% during the third quarter. Empirical Finance LLC now owns 15,606 shares of the biotechnology company’s stock worth $1,829,000 after purchasing an additional 1,190 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its holdings in United Therapeutics Corporation by 1.6% during the third quarter. State Board of Administration of Florida Retirement System now owns 77,438 shares of the biotechnology company’s stock worth $9,075,000 after purchasing an additional 1,226 shares during the last quarter. Wedge Capital Management L L P NC boosted its holdings in United Therapeutics Corporation by 21.8% during the third quarter. Wedge Capital Management L L P NC now owns 11,488 shares of the biotechnology company’s stock worth $1,346,000 after purchasing an additional 2,059 shares during the last quarter. Finally, Wedbush Securities Inc. acquired a new position in United Therapeutics Corporation during the third quarter worth $435,000.

Several research analysts recently commented on the stock. BidaskClub cut shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Monday, July 31st. ValuEngine cut shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. TheStreet cut shares of United Therapeutics Corporation from a “b-” rating to a “c” rating in a report on Friday, September 29th. Zacks Investment Research upgraded shares of United Therapeutics Corporation from a “strong sell” rating to a “hold” rating in a report on Monday, October 9th. Finally, Oppenheimer Holdings, Inc. restated a “buy” rating on shares of United Therapeutics Corporation in a report on Friday, September 8th. Five research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company. United Therapeutics Corporation currently has an average rating of “Hold” and a consensus target price of $132.82.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.watchlistnews.com/united-therapeutics-corporation-uthr-shares-bought-by-state-of-wisconsin-investment-board/1717379.html.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) opened at $126.20 on Tuesday. United Therapeutics Corporation has a 1 year low of $112.01 and a 1 year high of $169.89. The stock has a market cap of $5,430.00, a price-to-earnings ratio of 10.85 and a beta of 1.38.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.01 by $2.26. United Therapeutics Corporation had a net margin of 30.50% and a return on equity of 26.24%. The firm had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. During the same period in the prior year, the firm posted $4.23 earnings per share. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. equities analysts predict that United Therapeutics Corporation will post 12.29 EPS for the current fiscal year.

In other news, CEO Martine A. Rothblatt sold 1,238 shares of the stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of $130.65, for a total value of $161,744.70. Following the transaction, the chief executive officer now directly owns 2,307 shares of the company’s stock, valued at $301,409.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 1,235 shares of the stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $130.49, for a total transaction of $161,155.15. Following the completion of the transaction, the chief executive officer now directly owns 2,304 shares in the company, valued at $300,648.96. The disclosure for this sale can be found here. Insiders have sold 23,879 shares of company stock worth $2,926,931 over the last ninety days. Insiders own 7.80% of the company’s stock.

United Therapeutics Corporation Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.